# BriaCell (BCTX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/BCTX
## Company Profile
- Ticker: BCTX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Canada
- Tags: Immunotherapy, Oncology
## Stock Data
- Close: 3.92 USD
- Market cap: 23709092.49 USD
- Last updated: 2026-10-08
## Business Overview
### Cancer Immunotherapy Developer
BriaCell Therapeutics develops immunotherapies intended to stimulate coordinated immune responses against cancer. Its programs combine allogeneic tumor-cell platforms with checkpoint inhibitors and other immune-modulating agents.
### Bria-IMT in Metastatic Breast Cancer
Bria-IMT is an off-the-shelf whole-cell immunotherapy being evaluated with checkpoint blockade in metastatic breast cancer. The program has advanced into a pivotal Phase 3 study for patients who have exhausted multiple prior treatment options.
### Personalized Off-the-Shelf Platform
The Bria-OTS and Bria-BRES approaches use a bank of engineered cell lines selected according to patient immune characteristics. This design seeks to preserve personalization while avoiding the manufacturing time required for fully patient-specific cell therapies.
### Bria-BRES and Bria-PROS Expansion
Bria-BRES is being developed for breast cancer through a next-generation clinical program, while Bria-PROS extends the platform into prostate cancer. These programs broaden the company's pipeline beyond the lead Bria-IMT regimen.
### Combination-Oriented Development
BriaCell's strategy is to pair its cellular immunotherapies with checkpoint inhibitors and other agents that may reinforce antitumor immune activity. The company retains responsibility for clinical development while using external manufacturing and clinical partners.
### Biomarker-Guided Patient Selection
Clinical and translational work evaluates immune signatures and tumor characteristics associated with response. These biomarkers may help define the patients most likely to benefit from BriaCell's cellular regimens.
## Why The Stock Is Moving

As of Oct 8, 2026, BCTX closed down 2.00% at $3.92. No new same-company headline was identified in the current news window.

## Future Catalysts

- Initiation of the Phase 1/2a study of Bria-BRES+ following FDA clearance of the IND.

## Recent News
- 2026-10-06 11:30 EST — [BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting](https://biopharmsignal.com/news/BCTX/briacell-and-briapro-to-present-four-posters-at-sitc-2026-annual-meeting-1f598613) — Source: BriaCell
- 2026-09-14 11:30 EST — [Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study](https://biopharmsignal.com/news/BCTX/data-safety-monitoring-board-dsmb-recommends-continuing-briacell-s-phase-3-metas-3ce97282) — Source: BriaCell
- 2026-09-08 11:30 EST — [BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center](https://biopharmsignal.com/news/BCTX/briacell-s-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-can-ac14a722) — Source: BriaCell
- 2026-08-24 11:30 EST — [BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™](https://biopharmsignal.com/news/BCTX/briacell-advances-personalized-melanoma-immunotherapy-vaccine-candidate-bria-mel-f687a234) — Source: BriaCell
- 2026-08-05 11:30 EST — [BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer](https://biopharmsignal.com/news/BCTX/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cde0a86e) — Source: BriaCell